Latest News and Press Releases

SEATTLE, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the publication...

SEATTLE, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...

Goal is to report UP421 proof of concept data in 2023 and 2024 Potential to remove immunosuppression from islet cell transplantation SEATTLE, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology,...

Phase 1 trial to investigate multiple B-cell mediated autoimmune diseases First healthy donor-derived allogeneic CAR T cell therapy to announce IND clearance Expect to disclose initial clinical...

Enrolling Phase 1 ARDENT trial investigating SC291 in patients with refractory B-cell malignancies with initial data expected in 2023 and more robust data in 2024 CTA submitted for...

SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that five...

Increasing focus on ex vivo cell therapy platform based on extensive preclinical and early translational clinical data suggesting ability of hypoimmune (HIP)-modified cells to evade immune detection ...

SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...

Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year Expect data later this year from investigator-sponsored trial with...

Hypoimmune (HIP)-modified CD19-directed CAR T cells have the potential to serve as a universal off-the-shelf therapy that provides long-term durability of response without immunosuppression ...